Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daisuke Yabe

Showing results (41-50 of 253) with videos related to

Pageof 26
Sort By:
Journal of Diabetes Investigation|May 20, 2020
Cardioprotective effects of GLP-1(28-36a): A degraded metabolite or GLP-1's better half?Yangyang Liu, Sodai Kubota, Katsumi Iizuka, et al.
Diabetes, Obesity & Metabolism|September 2, 2021
Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trialKatsumi Iizuka, Mike Baxter, Daisuke Watanabe, et al.
Internal Medicine (Tokyo, Japan)|March 20, 2020
SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug ClassesKenta Nonomura, Katsumi Iizuka, Yayoi Kuwabara-Ohmura, et al.
Diabetes, Obesity & Metabolism|June 25, 2026
Cardiovascular Efficacy of GLP-1 Receptor Agonists by Kidney Function: An Updated Meta-Analysis of Randomized Trials Including the SOUL TrialMasashi Hasebe, Chen-Yang Su, Daisuke Yabe, et al.
Journal of Diabetes Investigation|May 7, 2024
PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in JapanRyo Suzuki, Hanan Amadid, Atheline Major-Pedersen, et al.
Current Medical Research and Opinion|April 29, 2015
Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-pointsDaisuke Yabe, Hitoshi Kuwata, Ryota Usui, et al.
American Journal of Epidemiology|April 16, 2025
Depression Risk Associated with Spouses' Diabetes and Cardiovascular Events: A Nationwide Cohort StudyToshiaki Komura, Yusuke Tsugawa, Daisuke Yabe, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 16, 2024
Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA JapanDaisuke Yabe, Munehide Matsuhisa, Yoko Takahashi, et al.
Journal of Diabetes Investigation|October 31, 2019
Ceritinib-associated hyperglycemia in the Japanese Adverse Drug Event Report DatabaseHaruka Fujita, Takaaki Murakami, Fumiaki Tomoike, et al.
Diabetes, Obesity & Metabolism|October 3, 2022
Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy)Daisuke Yabe, Dan Kawamori, Yusuke Seino, et al.
Pageof 26

Showing results (41-50 of 253) with videos related to

Sort By:
Pageof 26
Journal of Diabetes Investigation|May 20, 2020
Cardioprotective effects of GLP-1(28-36a): A degraded metabolite or GLP-1's better half?Yangyang Liu, Sodai Kubota, Katsumi Iizuka, et al.
Diabetes, Obesity & Metabolism|September 2, 2021
Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trialKatsumi Iizuka, Mike Baxter, Daisuke Watanabe, et al.
Internal Medicine (Tokyo, Japan)|March 20, 2020
SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug ClassesKenta Nonomura, Katsumi Iizuka, Yayoi Kuwabara-Ohmura, et al.
Diabetes, Obesity & Metabolism|June 25, 2026
Cardiovascular Efficacy of GLP-1 Receptor Agonists by Kidney Function: An Updated Meta-Analysis of Randomized Trials Including the SOUL TrialMasashi Hasebe, Chen-Yang Su, Daisuke Yabe, et al.
Journal of Diabetes Investigation|May 7, 2024
PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in JapanRyo Suzuki, Hanan Amadid, Atheline Major-Pedersen, et al.
Current Medical Research and Opinion|April 29, 2015
Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-pointsDaisuke Yabe, Hitoshi Kuwata, Ryota Usui, et al.
American Journal of Epidemiology|April 16, 2025
Depression Risk Associated with Spouses' Diabetes and Cardiovascular Events: A Nationwide Cohort StudyToshiaki Komura, Yusuke Tsugawa, Daisuke Yabe, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 16, 2024
Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA JapanDaisuke Yabe, Munehide Matsuhisa, Yoko Takahashi, et al.
Journal of Diabetes Investigation|October 31, 2019
Ceritinib-associated hyperglycemia in the Japanese Adverse Drug Event Report DatabaseHaruka Fujita, Takaaki Murakami, Fumiaki Tomoike, et al.
Diabetes, Obesity & Metabolism|October 3, 2022
Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy)Daisuke Yabe, Dan Kawamori, Yusuke Seino, et al.
Pageof 26